Dr. McDermott on an Analysis of the CheckMate-214 Study in RCC

David F. McDermott, MD
Published: Wednesday, Nov 14, 2018



David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses an analysis of the CheckMate-214 study in advanced renal cell carcinoma (RCC).

Findings from the CheckMate-214 trial showed that frontline treatment with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) reduced the risk of death by 32% compared with sunitinib (Sutent) for patients with metastatic RCC. The trial led to the FDA approval of the combination as a frontline treatment for intermediate- and poor-risk patients with advanced RCC.  

In an analysis presented at the 2018 ESMO Congress, investigators evaluated the treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab or sunitinib in patients with advanced RCC on the CheckMate-214 trial. Findings from this analysis showed that in patients with intermediate- or poor-risk disease, nivolumab plus ipilimumab was associated with a significantly longer TFI. Investigators noted that TFI should be considered as a part of the traditional efficacy measures when evaluating therapeutic options for patients with advanced RCC.
SELECTED
LANGUAGE


David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses an analysis of the CheckMate-214 study in advanced renal cell carcinoma (RCC).

Findings from the CheckMate-214 trial showed that frontline treatment with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) reduced the risk of death by 32% compared with sunitinib (Sutent) for patients with metastatic RCC. The trial led to the FDA approval of the combination as a frontline treatment for intermediate- and poor-risk patients with advanced RCC.  

In an analysis presented at the 2018 ESMO Congress, investigators evaluated the treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab or sunitinib in patients with advanced RCC on the CheckMate-214 trial. Findings from this analysis showed that in patients with intermediate- or poor-risk disease, nivolumab plus ipilimumab was associated with a significantly longer TFI. Investigators noted that TFI should be considered as a part of the traditional efficacy measures when evaluating therapeutic options for patients with advanced RCC.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x